Emilia Hadziyannis

Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir

Stephanos J. Hadziyannis, Vassilios Sevastianos, Irene Rapti et al. · Gastroenterology · 2012 · 346 citations · Full text

Pharmacy, Pharmacotherapy, Hepatitis Pharmacotherapy +10

Prediction of Treatment-Related HBsAg Loss in HBeAg-Negative Chronic Hepatitis B: A Clue from Serum HBsAg Levels

Emanuel K. Manesis, Emilia Hadziyannis, Olga P Angelopoulou et al. · Antiviral Therapy · 2007 · 157 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection

Dimitrios Vassilopoulos, Emilia Hadziyannis, George Papatheodoridis et al. · Annals of the Rheumatic Diseases · 2010 · 143 citations

Pharmacy, Immunology, Pharmacotherapy +15

DARING-B: Discontinuation of Effective Entecavir or Tenofovir Disoproxil Fumarate Long-Term Therapy before HBsAg Loss in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B

George Papatheodoridis, Eirini I. Rigopoulou, Μargarita Papatheodoridi et al. · Antiviral Therapy · 2017 · 95 citations

Pharmacy, Pharmacotherapy, Hepatic Pharmacotherapy +16

Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity

Emmanuel Tsochatzis, George Papatheodoridis, Emilia Hadziyannis et al. · Scandinavian Journal of Gastroenterology · 2008 · 85 citations

Medicine, Internal Medicine, Pathology +14